Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19.
Adv Biol Regul
; 81: 100818, 2021 08.
Article
in English
| MEDLINE | ID: covidwho-1313202
ABSTRACT
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is characterized by a wide spectrum of symptom severity, which is manifested at different phases of infection and demands different levels of care. Viral load, host innate-immune response to SARS-CoV-2, and comorbidities have a direct impact on the clinical outcomes of COVID-19 patients and determine the diverse disease trajectories. The initial SARS-CoV-2 penetrance and replication in the host causes death of infected cells, determining the viral response. SARS-CoV-2 replication in the host triggers the activation of host antiviral immune mechanisms, determining the inflammatory response. While a healthy immune response is essential to eliminate infected cells and prevent spread of the virus, a dysfunctional immune response can result in a cytokine storm and hyperinflammation, contributing to disease progression. Current therapies for COVID-19 target the virus and/or the host immune system and may be complicated in their efficacy by comorbidities. Here we review the evidence for use of two classes of anti-inflammatory drugs, glucocorticoids and nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of COVID-19. We consider the clinical evidence regarding the timing and efficacy of their use, their potential limitations, current recommendations and the prospect of future studies by these and related therapies.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Virus Replication
/
Anti-Inflammatory Agents, Non-Steroidal
/
SARS-CoV-2
/
COVID-19 Drug Treatment
/
Glucocorticoids
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Adv Biol Regul
Year:
2021
Document Type:
Article
Affiliation country:
J.jbior.2021.100818
Similar
MEDLINE
...
LILACS
LIS